knowledge -WSS

knowledge

author：knowledge 2025-08-12 09:13:09 - browse：99756

Adam's take main illustration — Molly Ferguson/STAT

It took Anavex Life Sciences seven months to finally acknowledge the failure of a late-stage clinical trial in Rett syndrome.

The negative study outcome was never in doubt, so the only surprise from Tuesday’s announcement was the company’s lame attempt at damage control. Anavex is a serial dissembler of clinical trial results, so I was expecting better spin. Instead, management barely tried, which tells you the real results from the Rett study must be truly awful.

Anavex shares fell 31% to $6 in early trading. The company’s only drug in clinical development, called blarcamesine, is a zero. Rett is the latest failure, following earlier study failures in Alzheimer’s disease and Parkinson’s disease. Yet even with Tuesday’s drop in share price, Anavex still carries a fully diluted market value of nearly $650 million.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： Target recalls 2.2 million additional candles due to laceration, burn hazards

leisure time

WSS

House GOP releases memo on Hunter Biden foreign business dealings, reviving old claims

'Reaching a detente': STAT's Helen Branswell on covering Covid

Faced with fears of OxyContin misuse, sales reps touted its safety

Gilgo Beach murders: What questions remain following Rex Heuermann's arrest?

Resistance to cancer drugs: A new genetic explanation

States increasingly look to regulate hospital facility fees

knowledge

knowledge

explore

Medicare proposal to cover medical devices draws a mixed reaction

House GOP releases memo on Hunter Biden foreign business dealings, reviving old claims

Anesthesiologist group: stop taking Ozempic before surgery

O'Shea Sibley was killed after expressing queer joy by voguing, activists say

ChatGPT in medicine: STAT answers readers' burning questions

Couple fighting to bring baby home from Mexico are finally reunited

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

States increasingly look to regulate hospital facility fees

Virginia high school admissions case could be legal follow

Large hospital system sues Multiplan for low

explore

'Disease catastrophe' looms in Sudan as health conditions deteriorate, medics warn

Newly revealed memo details efforts to keep Trump in power following election loss

TB outbreak tied to bone grafts underscores testing shortcomings

O'Shea Sibley was killed after expressing queer joy by voguing, activists say

CDC overhauls leadership of center that led response to Covid

No Labels group has 'steep climb,' but third party 'worth trying': Larry Hogan

leisure time

leisure time

leisure time

hotspot